Clinical Trials Browser

Phase 1 × Recruiting × Specimen Handling × Clear all

NCT06465316 2026-05-27

Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma

Phase 1 Recruiting

Multiple Myeloma

NCT06914479 2026-05-27

Virus-Based Gene Therapy (AdV-HSV1-TK and AdV-Flt3L) in Combination With Valacyclovir for the Treatment of Pediatric and Young Adult Patients With Resectable, Recurrent Primary Malignant Brain Tumors

Phase 1 Recruiting

Brain Neoplasms

NCT07012044 2026-05-27

A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia

Phase 1 Recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT07137416 2026-05-27

Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer

Phase 1 Recruiting

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT04633239 2026-05-22

Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer

Phase 1 Recruiting

Recurrent Ovarian High Grade Serous Adenocarcinoma

NCT05886049 2026-05-22

Testing the Addition of an Anti-cancer Drug, SNDX-5613, to the Standard Chemotherapy Treatment (Daunorubicin and Cytarabine) for Newly Diagnosed Patients With Acute Myeloid Leukemia That Has Changes in NPM1 or MLL/KMT2A Gene

Phase 1 Recruiting

MyeloidOther hematologic neoplasm

Acute Myeloid Leukemia With KMT2A Rearrangement

NCT06763341 2026-05-22

A Phase 1 Study of AOH1996 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Phase 1 Recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT04585958 2026-05-20

Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer

Phase 1 Recruiting

Neoplasm Metastasis

NCT05418088 2026-05-20

Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies

Phase 1 Recruiting

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Prolymphocytic, B-Cell

NCT05989828 2026-05-19

A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer

Phase 1 Recruiting

Triple Negative Breast Neoplasms

NCT05172245 2026-05-18

Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer

Phase 1 Recruiting

Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT06287944 2026-05-18

225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome

Phase 1 Recruiting

LymphoidMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05711615 2026-05-15

Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma

Phase 1 Recruiting

Leiomyosarcoma, Liposarcoma, Sarcoma, Sarcoma, Synovial, Dermatofibrosarcoma, Histiocytoma, Malignant Fibrous

NCT06894979 2026-05-15

Testing the Addition of an Anti-Cancer Drug, AZD1390, During Radiation Therapy for Newly Diagnosed High Grade Glioma, Diffuse Midline Glioma, or Diffuse Intrinsic Pontine Glioma

Phase 1 Recruiting

Astrocytoma

NCT06222580 2026-05-14

SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation

Phase 1 Recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT03816345 2026-05-13

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

Phase 1 Recruiting

Other hematologic neoplasm

Arthritis, Rheumatoid, Autoimmune Diseases, Colitis, Ulcerative, Crohn Disease, Dermatomyositis, Lupus Erythematosus, Systemic, Multiple Sclerosis, Psoriasis, Scleroderma, Systemic, Sjogren's Syndrome, Inflammatory Bowel Diseases, Arthritis, Psoriatic, Hematologic Neoplasms

NCT05272384 2026-05-13

Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma

Phase 1 Recruiting

Hodgkin Disease, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT05372640 2026-05-13

Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors

Phase 1 Recruiting

Breast Neoplasms, Neoplasm Metastasis

NCT05411094 2026-05-13

Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer

Phase 1 Recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT05422794 2026-05-13

Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer

Phase 1 Recruiting

Triple Negative Breast Neoplasms

NCT05630794 2026-05-13

Testing for Safety and Colorectal Cancer Preventive Effects of ONC201

Phase 1 Recruiting

Gastrointestinal

Adenomatous Polyposis Coli, Colorectal Neoplasms

NCT05673200 2026-05-13

Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer

Phase 1 Recruiting

Triple Negative Breast Neoplasms

NCT05687110 2026-05-13

Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes

Phase 1 Recruiting

Neoplasm Metastasis

NCT05687123 2026-05-13

Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors

Phase 1 Recruiting

Gastrointestinal

Adenoma, Islet Cell, Pancreatic Neoplasms

NCT05687136 2026-05-13

Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and Tuvusertib (M1774) for Advanced Solid Tumors

Phase 1 Recruiting

Neoplasm Metastasis

NCT05691517 2026-05-13

Testing How the Body Responds to the Drug CBX-12 in Patients With Advanced Solid Cancers

Phase 1 Recruiting

Neoplasm Metastasis

NCT05803382 2026-05-13

Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers

Phase 1 Recruiting

Gastrointestinal

Neoplasm Metastasis, Colorectal Neoplasms

NCT05985681 2026-05-13

Testing RG1-VLP Vaccine to Prevent HPV-related Cancers

Phase 1 Recruiting

Human Papillomavirus-Related Carcinoma

NCT06015880 2026-05-13

Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Phase 1 Recruiting

Lymphoma, Large B-Cell, Diffuse

NCT06058663 2026-05-13

Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic Cholangiocarcinoma

Phase 1 Recruiting

Gastrointestinal

Cholangiocarcinoma

NCT06223542 2026-05-13

Studying TAK-243 in Patients With Advanced Cancer

Phase 1 Recruiting

Neoplasm Metastasis

NCT06364410 2026-05-13

Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors

Phase 1 Recruiting

Gastrointestinal

Neoplasm Metastasis, Stomach Neoplasms

NCT06439836 2026-05-13

Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy

Phase 1 Recruiting

Carcinoma, Transitional Cell

NCT06484062 2026-05-13

Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes

Phase 1 Recruiting

MyeloidOther hematologic neoplasm

GATA2 Deficiency, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT06606990 2026-05-13

Testing How the Body Responds to the Drug CX-5461 (Pidnarulex) in Patients With Metastatic Solid Cancers

Phase 1 Recruiting

Neoplasm Metastasis

NCT06654037 2026-05-13

Testing the Addition of an Anti-Cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (5-Fluorouracil) for Metastatic, Refractory Colorectal Cancer

Phase 1 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT06696768 2026-05-13

Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer

Phase 1 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT05950464 2026-05-11

Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer

Phase 1 Recruiting

Endometrial Neoplasms

NCT06996119 2026-05-11

Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant

Phase 1 Recruiting

MyeloidOther hematologic neoplasm

Graft vs Host Disease, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT07128680 2026-05-11

Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer

Phase 1 Recruiting

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

NCT06964737 2026-05-08

Anti-GARP Chimeric Antigen Receptor T Cell Therapy for the Treatment of Recurrent Grade III or IV Gliomas

Phase 1 Recruiting

Glioma

NCT07544992 2026-05-06

Locoregional Administration of Genetically Engineered Cells (EGFR/IL13Rα2 Pool-CAR T Cells) for the Treatment of Recurrent or Progressive High-Grade Gliomas

Phase 1 Recruiting

Astrocytoma, Glioblastoma

NCT03025256 2026-05-05

Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease

Phase 1 Recruiting

DermatologicThoracic

Uveal Melanoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Melanoma, Meningeal Neoplasms, Nevus

NCT05521698 2026-05-05

A Randomized Trial of Bicalutamide in Non-Muscle Invasive Bladder Cancer

Phase 1 Recruiting

Non-Muscle Invasive Bladder Urothelial Carcinoma

NCT06410248 2026-05-01

Triapine in Combination With Temozolomide for the Treatment of Patients With Recurrent Glioblastoma

Phase 1 Recruiting

Glioblastoma

NCT06195891 2026-04-29

Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome

Phase 1 Recruiting

LymphoidMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05030298 2026-04-22

Preoperative Radiosurgery for the Treatment of High Grade Glioma, NeoGlioma Trial

Phase 1 Recruiting

Glioma

NCT06247787 2026-04-20

A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy

Phase 1 Recruiting

Other hematologic neoplasm

Leukemia, Myelomonocytic, Juvenile

NCT06859008 2026-04-20

Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Phase 1 Recruiting

LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT07025538 2026-04-20

Biomarker-Guided Ruxolitinib for the Prevention of Chronic Graft Versus Host Disease After Allogeneic Hematopoietic Cell Transplantation

Phase 1 Recruiting

Hematopoietic and Lymphatic System Neoplasm